Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted an NDA for paliperidone palmitate to the FDA. The drug — a once-monthly atypical antipsychotic intramuscular injection for the treatment of schizophrenia — is a long-acting injectable ester of the API in Invega, which utilizes  NanoCrystal Technology developed by Elan. Upon approval, paliperidone palmitate will be marketed in the U.S. by Janssen, L.P. Under the terms of Elan’s licen...